28 completed, 24 recruiting, 24 unknown, 9 not yet recruiting. 58 Phase 2, 29 Phase 1, 23 Phase 3, 1 Not applicable, 1 Phase 4.
Follow RemeGen Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation RC48-ADC, Pyrotinib - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | RemeGen Co., Ltd. | 26 | 2027-12-01 | 2026-09-22 |
| Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer RC148 plus Telisotuzumab adizutecan, Telisotuzumab adizutecan plus Bevacizumab - Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy | Phase 2 | Not yet recruiting | RemeGen Co., Ltd. | 412 | 2026-11-01 | 2026-10-26 |
| Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148 as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung Cancer Telisotuzumab adizutecan plus RC148 - Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or Cytology | Phase 2 | Not yet recruiting | RemeGen Co., Ltd. | 200 | 2026-11-01 | 2026-10-14 |
| Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations RC148 Injection plus Pemetrexed Disodium for Injection and Carboplatin Injection, Tislelizumab Injection plus Pemetrexed Disodium for Injection and Carboplatin Injection - Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations | Phase 3 | Not yet recruiting | RemeGen Co., Ltd. | 540 | 2026-09-30 | 2026-09-22 |
| A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer RC148 (Dose 1) plus Capecitabine and Oxaliplatin, RC148 (Dose 2) plus Capecitabine and Oxaliplatin - Colorectal (Colon or Rectal) Cancer | Phase 2 / Phase 3 | Recruiting | RemeGen Co., Ltd. | 80 | 2026-05-12 | 2026-05-22 |
| Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma Disitamab Vedotin (RC48), radiotherapy, Gemcitabine (1000 mg/m2) - Upper Tract Urothelial Carcinoma | Phase 3 | Recruiting | Peking University First Hospital | 192 | 2026-05-01 | 2026-09-28 |
| A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors RC288 For Injection - Solid Tumors | Phase 1 / Phase 2 | Recruiting | RemeGen Co., Ltd. | 326 | 2026-04-27 | 2026-09-23 |
| Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease Telitacicept, Placebo - CTD-ILD | Phase 3 | Not yet recruiting | RemeGen Co., Ltd. | 260 | 2026-04-20 | 2026-04-09 |
| RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) RC148 plus Carboplatin and Paclitaxel, Tislelizumab plus Carboplatin and Paclitaxel - Non-Small Cell Lung Cancer | Phase 3 | Recruiting | RemeGen Co., Ltd. | 574 | 2026-04-03 | 2026-07-14 |
| A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer Tunlametinib+PD-1 mAb - Gastric Adenocarcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 76 | 2026-04-01 | 2026-04-02 |
| A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) Telitacicept, Placebo - Myasthenia Gravis, Ocular | Phase 3 | Recruiting | RemeGen Co., Ltd. | 120 | 2026-01-13 | 2026-04-09 |
| A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Disitamab Vedotin, Tislelizumab, CAPOX (oxaliplatin/capecitabine) - Gastric Carcinoma | Phase 3 | Recruiting | RemeGen Co., Ltd. | 555 | 2026-01-12 | 2026-09-22 |
| RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients Disitamab Vedotin combined with Radiotherapy - HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT | Phase 2 | Not yet recruiting | Peking University First Hospital | 30 | 2025-09-01 | 2025-08-03 |
| A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors RC278 - Solid Tumors | Phase 1 / Phase 2 | Recruiting | RemeGen Co., Ltd. | 312 | 2025-08-11 | 2025-11-26 |
| A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC RC108, Furmonertinib Mesilate Tablets Monotherapy - Non-Small Cell Lung Cancer | Phase 2 | Recruiting | RemeGen Co., Ltd. | 80 | 2025-06-30 | 2025-07-16 |
| A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine, Tislelizumab+Oxaliplatin+Capecitabine - Gastric Carcinoma | Phase 3 | Not yet recruiting | RemeGen Co., Ltd. | 616 | 2025-05-15 | 2025-04-25 |
| A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC RC148 plus Carboplatin and Paclitaxel/pemetrexed, RC148 - Non-Small Cell Lung Cancer | Phase 1 | Active not recruiting | RemeGen Co., Ltd. | 121 | 2025-03-13 | 2026-03-05 |
| Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer Disitamab Vedotin, RC148, Albumin-bound Paclitaxone - Breast Cancer | Phase 2 | Recruiting | RemeGen Co., Ltd. | 40 | 2025-02-10 | 2025-02-17 |
| Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer Disitamab Vedotin, Toripalimab - Breast Neoplasms | Phase 2 | Withdrawn | RemeGen Co., Ltd. | 2024-12-20 | 2024-08-23 | |
| Neoadjuvant Therapy in Cervical Cancer Disitamab Vedotin and Cisplatin - Uterine Cervical Neoplasms | Not applicable | Recruiting | Qilu Hospital of Shandong University | 48 | 2024-10-20 | 2025-04-01 |
Showing 20 of 95. Sign in to see all of them.
Stomach Neoplasms (10) · Breast Neoplasms (8) · Carcinoma, Non-Small-Cell Lung (6) · Carcinoma, Transitional Cell (6) · Lupus Erythematosus, Systemic (5) · Non-Muscle Invasive Bladder Neoplasms (5) · Autoimmune Diseases (3) · Glomerulonephritis, IGA (3) · Arthritis, Rheumatoid (2) · Lymphoma, Follicular (2) · Melanoma (2) · Myasthenia Gravis (2) · Uterine Cervical Neoplasms (2) · Biliary Tract Neoplasms (1) · Breast Diseases (1)
Injections (22) · disitamab vedotin (20) · RC-18 (12) · telitacicept (11) · toripalimab (9) · Carboplatin (7) · tislelizumab (6) · Capecitabine (5) · Paclitaxel (5) · Gemcitabine (4) · Oxaliplatin (4) · Standard of Care (4) · Cisplatin (3) · RC28-E protein (3) · RC48 antibody (3)
China (89) · Australia (4) · United States (3) · Canada (2) · Italy (2) · Japan (2) · South Korea (2) · Spain (2) · Taiwan (2) · United Kingdom (2) · Argentina (1) · Belgium (1) · Brazil (1) · Chile (1) · Czechia (1)
Jianmin Fang, Ph.D (10) · Jun Guo, Ph.D (3) · Binghe Xu (2) · Fengchun Zhang (2) · Na Su, PhD (2) · Tianshu Liu, ph.D (2) · Aimin Zang (1) · Airong Wang (1) · Beihua Kong, M.D (1) · Changling Li (1) · Changlu Hu (1) · Chunde Bao (1) · Fengchun Zhang, M.D. (1) · Guohua Yu (1)
PMID 38299639, PMID 37988648, PMID 38940019, PMID 31652997, PMID 33109737, PMID 33945049, PMID 34665942, PMID 37399108, PMID 38129117, PMID 38235421, PMID 38726639, PMID 40112819, PMID 40122579, PMID 40465397, PMID 40661136, PMID 41092329, PMID 41124210, PMID 41408192, PMID 42127391, PMID 42802176
2023 (1)